Curing the Drug Label as Prior Art Malady at the PTAB

April 21, 2026

Informa 35th Annual Advanced EU London Conference

On April 21, Axinn partner Katrina Rouse will speak on the "Defence Readiness Omnibus: Competition Law Considerations" panel at Informa's Advanced EU London Conference, being held April 21-22.

Speaking Engagement

Antitrust

April 13, 2026

AHLA Health Care Transactions Program 2026

Axinn is proud to sponsor the American Health Law Association’s Health Care Transactions Program, being held April 13-15 in Nashville, Tennessee.

Sponsorship

Antitrust

March 25, 2026

Axinn Partners John Harkrider and Craig Minerva Win 2026 Concurrences Antitrust Writing Award

John Harkrider and Craig Minerva won a 2026 Concurrences Antitrust Writing Award for their article “Antitrust in a Time of Trade War.” The article was recognized in the Business, Cross-Border category.

Awards & Recognitions

Antitrust

March 25, 2026

Axinn Wins Firm of the Year – Americas at 2026 Global Competition Review Awards

Axinn is proud to announce that it was named GCR “Firm of the Year – Americas,” recognizing an exceptional year defined by the quality and impact of the firm’s antitrust work. This is the fourth time the firm has won this award, reflecting Axinn’s continued growth, deep bench of talent, and success guiding clients through complex, high-stakes competition matters.

Awards & Recognitions

Antitrust

March 23, 2026

IPWatchdog Sixth Annual Live Conference

On March 23, Axinn partner Brian Johnson will speak on the "Winning ITC Strategy: A Practitioner’s Guide to 337 Litigation" panel at IPWatchdog's sixth annual Live Conference, being held March 22-24 in Arlington, Virginia.

Speaking Engagement

Intellectual Property

March 23, 2026

Is Any Deal Safe From Review in the EU? Implications of the “Towercast” Judgment

M&A deals affecting the EU that fall outside standard merger control thresholds may still be subject to review under general competition law—but how does that work? In this episode, Axinn partner James Hunsberger and co-host Matthew Hall (McGuireWoods) explore the implications of the European Court of Justice’s 2023 “Towercast” judgment with guest Frédéric Manin (Advant Altana).

Podcast

Antitrust

March 20, 2026

Axinn Antitrust Insight: HSR Overhaul: Out with the New, In with the Old

After more than a year in effect, the FTC’s burdensome new rule for HSR filings has been suspended. Effective immediately, parties to...

Axinn Viewpoints

Antitrust

March 19, 2026

The DOJ's Whistleblower Program and Leniency

The DOJ Antitrust Division's new Whistleblower Rewards Program could have negative unintended consequences for the leniency program and...

Axinn Viewpoints

Antitrust

March 13, 2026

Squires Again Broadens Discretion for Post-Grant Proceedings

On Wednesday, March 11, 2026, United States Patent and Trademark Office (USPTO) Director John Squires issued a memorandum[1] announcing...

Axinn Viewpoints

Intellectual Property

March 11, 2026

ABA White Collar Crime Institute 2026

On March 11, Axinn partner Jacklin Chou Lem will moderate the "Trends and Recent Developments in Criminal Antitrust Enforcement" panel at the American Bar Association's White Collar Crime Institute, being held March 10-13 in San Diego.

Speaking Engagement

March 10, 2026

Back to the Well: FDA’s Draft Guidance on New Clinical Investigation Exclusivity

Introduction FDA recently published a new draft Guidance for Industry titled “New Clinical Investigation Exclusivity (3-Year Exclusivity)...

Axinn Viewpoints

Intellectual Property

March 9, 2026

Mother, May I? The Use of Prior Approval Requirements in Merger Settlements

Federal enforcers continue to refine the tools they use in merger enforcement—including the use of prior approval provisions, once considered an extraordinary remedy in merger settlements. In this episode, Managing Partner Jeny Maier joins co-host Anora Wang in conversation with former FTC policy leader Bilal Sayyed to examine how these provisions have evolved across administrations and what their changing use reveals about current agency policy.

Podcast

Antitrust

Curing the Drug Label as Prior Art Malady at the PTAB

Related People

Related Services

Featured Insights

Featured Insights